Income Statement Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06/09/2024			5-day change	1st Jan Change
191,200.00 ^KRW	+1.70%		-5.81%	-5.11%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

b6a128445ae7d19f2a4b5e018df8f.PJCvpPCzCtd6S6rRV4rA2l9504lR6B1wpYQlUUS4OgI.X_fr7bfjZI4VPvDlE-2Rri4hq_oUmngHytxBAQ_QaVZdz5fPu8JPiBw4kg

Published financial data: CELLTRION, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	1,128B	1,849B	1,912B	2,284B	2,176B
Other Revenues, Total	110	-110	-30	-10	-10
Total Revenues	1,128B	1,849B	1,912B	2,284B	2,176B
Cost of Goods Sold, Total	495B	821B	806B	1,251B	1,125B
Gross Profit	633B	1,028B	1,106B	1,033B	1,052B
Selling General & Admin Expenses, Total	132B	127B	186B	205B	203B
Provision for Bad Debts	-3.39M	-1.69M	14.31M	-1.69M	-5.03B
R&D Expenses	114B	171B	126B	140B	161B
Depreciation & Amortization - (IS)	2.97B	3.19B	2.8B	3.46B	5.35B
Amortization of Goodwill and Intangible Assets - (IS)	3.83B	7.84B	34.25B	37.35B	35.61B
Other Operating Expenses, Total	252B	309B	349B	385B	400B
Operating Income	382B	719B	757B	647B	651B
Interest Expense, Total	-10.83B	-7.5B	-8.24B	-7.51B	-9.67B
Interest And Investment Income	12.06B	5.72B	4.4B	14.22B	19.06B
Net Interest Expenses	1.23B	-1.78B	-3.84B	6.71B	9.4B
Income (Loss) On Equity Invest.	4.54B	2.59B	-4.97B	7.35B	-12.68B
Currency Exchange Gains (Loss)	452M	-22.74B	32.91B	16.99B	11.62B
Other Non Operating Income (Expenses)	-7.89B	-41.98B	-6.31B	-41.41B	355M
EBT, Excl. Unusual Items	380B	655B	775B	637B	660B
Gain (Loss) On Sale Of Investments	21.17M	15.62B	1.15B	-	1.51B
Gain (Loss) On Sale Of Assets	4.54B	-8.86B	32.88B	828M	13.35B
Asset Writedown	-2.4B	-4.27B	-57.35B	-11.49B	-3.88B
Insurance Settlements	-	-	-	-	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	382B	657B	751B	626B	671B
Income Tax Expense	80.59B	131B	156B	94.83B	131B
Earnings From Continuing Operations	301B	526B	596B	531B	540B
Earnings Of Discontinued Operations	-	-	-	11.22B	-
Net Income to Company	301B	526B	596B	543B	540B
Minority Interest	-412M	-7.94B	-16.31B	-4.73B	-4.06B
Net Income - (IS)	301B	518B	579B	538B	536B
Net Income to Common Incl Extra Items	301B	518B	579B	538B	536B
Net Income to Common Excl. Extra Items	301B	518B	579B	527B	536B
Per Share Items
Net EPS - Basic	2.08K	3.58K	4K	3.74K	3.76K
Basic EPS - Continuing Operations	2.08K	3.58K	4K	3.67K	3.76K
Basic Weighted Average Shares Outstanding	144M	145M	145M	144M	142M
Net EPS - Diluted	2.05K	3.52K	3.95K	3.74K	3.75K
Diluted EPS - Continuing Operations	2.05K	3.52K	3.95K	3.66K	3.75K
Diluted Weighted Average Shares Outstanding	145M	145M	146M	144M	143M
Normalized Basic EPS	1.64K	2.77K	3.23K	2.74K	2.87K
Normalized Diluted EPS	1.63K	2.76K	3.22K	2.73K	2.86K
Dividend Per Share	-	-	707.01	360.58	500
Payout Ratio	-	-	0	19.05	9.64
Supplemental Items
EBITDA	535B	892B	971B	874B	897B
EBITA	487B	835B	909B	809B	833B
EBIT	382B	719B	757B	647B	651B
EBITDAR	536B	893B	971B	874B	898B
Effective Tax Rate - (Ratio)	21.09	20	20.7	15.14	19.58
Total Current Taxes	-	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	237B	401B	468B	393B	409B
Interest Capitalized	-	-	8.13B	16.38B	32.62B
Supplemental Operating Expense Items
Advertising Expense	7.99B	5.25B	12.77B	15.09B	17.33B
Selling and Marketing Expenses	51.33B	32.85B	53.4B	59.67B	76.92B
General and Administrative Expenses	2.68B	8.01B	22.8B	3.3B	7.23B
Research And Development Expense From Footnotes	114B	171B	126B	140B	161B
Net Rental Expense, Total	397M	279M	337M	345M	370M
Imputed Operating Lease Interest Expense	67.94M	26.38M	-	-	-
Imputed Operating Lease Depreciation	329M	253M	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	7.87B	8.52B	9.46B	11.23B	11.98B
Total Stock-Based Compensation	7.87B	8.52B	9.46B	11.23B	11.98B

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	546B	684B	1,188B	551B	565B
Short Term Investments	81.67B	14.03B	31.58B	43.28B	193B
Trading Asset Securities, Total	13.85M	-	-	-	-
Total Cash And Short Term Investments	628B	698B	1,220B	594B	757B
Accounts Receivable, Total	814B	1,252B	1,101B	1,622B	939B
Other Receivables	12.37B	63.32B	20.82B	13.15B	8.82B
Notes Receivable	0	0	42.47B	19.05B	1.25B
Total Receivables	827B	1,316B	1,164B	1,654B	949B
Inventory	307B	384B	578B	616B	3,041B
Prepaid Expenses	8.32B	10.2B	11.3B	13.43B	17.77B
Other Current Assets, Total	15.52B	108B	101B	51.46B	115B
Total Current Assets	1,785B	2,516B	3,074B	2,930B	4,881B
Gross Property Plant And Equipment	1,293B	1,359B	1,423B	1,544B	1,816B
Accumulated Depreciation	-369B	-412B	-473B	-537B	-602B
Net Property Plant And Equipment	924B	946B	950B	1,007B	1,215B
Long-term Investments	65.47B	79.37B	89.28B	118B	135B
Goodwill	3.03B	62.92B	33.01B	35.16B	11,475B
Other Intangibles, Total	45.86B	275B	287B	265B	502B
Accounts Receivable Long-Term	0	0	0	62.89B	0
Loans Receivable Long-Term	0	0	0	131M	131M
Deferred Tax Assets Long-Term	23.31B	28.99B	28.62B	32.18B	63.47B
Deferred Charges Long-Term	959B	1,066B	1,172B	1,322B	1,358B
Other Long-Term Assets, Total	53.96B	44.8B	39.77B	119B	287B
Total Assets	3,860B	5,020B	5,674B	5,892B	19,918B
Liabilities
Accounts Payable, Total	42.7B	33.96B	80.72B	50.27B	50.85B
Accrued Expenses, Total	96.88B	131B	139B	157B	187B
Short-term Borrowings	298B	437B	512B	554B	1,608B
Current Portion of Long-Term Debt	52.04B	132B	54.48B	81.43B	168B
Current Portion of Leases	2.21B	2.42B	3.01B	2.73B	8.17B
Current Income Taxes Payable	42.5B	100B	180B	88.7B	57.04B
Unearned Revenue Current, Total	2.41B	3.43B	3.58B	6.77B	21.71B
Other Current Liabilities	120B	216B	238B	353B	370B
Total Current Liabilities	657B	1,057B	1,210B	1,294B	2,471B
Long-Term Debt	140B	200B	170B	152B	99.13B
Long-Term Leases	3.56B	3.09B	4.37B	2.89B	7.98B
Unearned Revenue Non Current	31.86B	31.25B	28.23B	23.01B	77.4B
Pension & Other Post Retirement Benefits	-	-	-	3.35B	-
Deferred Tax Liability Non Current	67.24B	86.21B	21.58B	1.11B	120B
Other Non Current Liabilities	87.34B	215B	189B	141B	17.1B
Total Liabilities	987B	1,593B	1,624B	1,617B	2,792B
Common Stock, Total	128B	135B	138B	141B	220B
Additional Paid In Capital	801B	828B	856B	871B	14,790B
Retained Earnings	1,964B	2,475B	3,052B	3,485B	3,964B
Treasury Stock	-177B	-192B	-226B	-502B	-2,204B
Comprehensive Income and Other	43.79B	61.49B	96.23B	144B	211B
Total Common Equity	2,760B	3,308B	3,917B	4,139B	16,981B
Minority Interest	113B	120B	133B	135B	145B
Total Equity	2,873B	3,428B	4,050B	4,274B	17,126B
Total Liabilities And Equity	3,860B	5,020B	5,674B	5,892B	19,918B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	145M	145M	145M	143M	207M
ECS Total Common Shares Outstanding	145M	145M	145M	143M	207M
Book Value / Share	19.1K	22.85K	27.03K	28.89K	81.95K
Tangible Book Value	2,711B	2,970B	3,598B	3,839B	5,003B
Tangible Book Value Per Share	18.76K	20.52K	24.82K	26.79K	24.14K
Total Debt	495B	774B	744B	792B	1,890B
Net Debt	-132B	76.07B	-476B	198B	1,133B
Debt Equivalent Oper. Leases	3.17B	2.23B	2.69B	2.76B	2.96B
Minority Interest, Total (Incl. Fin. Div)	113B	120B	133B	135B	145B
Equity Method Investments, Total	47.84B	48.03B	64.84B	88.54B	105B
Account Code - Inventory Valuation	-	-	-	-	-
Inventories - Raw Materials, Total	117B	187B	245B	295B	279B
Inventories - Work In Process, Total	14.47B	26.62B	39.7B	48.31B	78.63B
Inventories - Finished Goods, Total	184B	195B	359B	365B	2,727B
Inventories - Others	735M	904M	2.2B	11.51B	10.2B
Land - (BS)	292B	302B	302B	302B	302B
Buildings, Total	350B	372B	373B	373B	601B
Machinery, Total	590B	630B	684B	700B	723B
Accumulated Allowance for Doubtful Accounts (Supple)	1.09B	1.07B	1.36B	1.53B	313M

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	301B	518B	579B	538B	536B
Depreciation & Amortization - CF	48.36B	57.66B	61.96B	64.72B	63.78B
Amortization of Goodwill and Intangible Assets - (CF)	105B	116B	152B	162B	182B
Depreciation & Amortization, Total	154B	174B	214B	226B	246B
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	2.05B	180M	-23.92B	880M	-1.96B
(Gain) Loss on Sale of Investments - (CF)	-6.61B	-6.94B	-10B	-838M	-12.83B
Asset Writedown & Restructuring Costs	2.4B	4.27B	57.23B	10.62B	3.82B
(Income) Loss On Equity Investments - (CF)	-4.54B	-2.59B	4.97B	-15.68B	12.68B
Stock-Based Compensation (CF)	17.81B	20.22B	22.05B	25.73B	27.77B
Provision and Write-off of Bad Debts	277M	323M	-235M	7.51B	-5.08B
Other Operating Activities, Total	28.56B	151B	67.83B	-43.44B	-47.3B
Change In Accounts Receivable	-7.5B	-537B	109B	-683B	-296B
Change In Inventories	-172B	-130B	-268B	-215B	57.25B
Change In Accounts Payable	22.1B	-7.85B	44.08B	53.57B	-2.19B
Change in Other Net Operating Assets	137B	167B	114B	96.19B	19.53B
Cash from Operations	474B	351B	911B	864M	537B
Capital Expenditure	-94.28B	-87.01B	-63.38B	-111B	-210B
Sale of Property, Plant, and Equipment	2.62B	3.16B	13.42M	3.46M	11.51M
Cash Acquisitions	-	-	-	-3.49B	374B
Divestitures	7.55B	-	-	17.49B	-
Sale (Purchase) of Intangible assets	-191B	-453B	-230B	-201B	-141B
Investment in Marketable and Equity Securities, Total	18.62B	58.13B	-57.03B	-39.37B	-186B
Other Investing Activities, Total	5.54B	6.62B	-5.07B	40.29B	23.55B
Cash from Investing	-251B	-472B	-356B	-297B	-139B
Short Term Debt Issued, Total	-	-	-	-	-
Long-Term Debt Issued, Total	213B	439B	207B	181B	828B
Total Debt Issued	213B	439B	207B	181B	828B
Short Term Debt Repaid, Total	-	-	-	-	-
Long-Term Debt Repaid, Total	-242B	-162B	-243B	-135B	-206B
Total Debt Repaid	-242B	-162B	-243B	-135B	-206B
Issuance of Common Stock	18.58B	19.4B	21.49B	9.86B	7.36B
Repurchase of Common Stock	-58.16B	-15.87B	-39.13B	-281B	-919B
Common Dividends Paid	-	-	-	-	-
Common & Preferred Stock Dividends Paid	-	-	-3.78M	-102B	-51.66B
Common & Preferred Stock Dividends Paid	-	-	-3.78M	-102B	-51.66B
Other Financing Activities, Total	-17.38B	-14.88B	-16.04B	-22.7B	-43.95B
Cash from Financing	-85.92B	266B	-69.28B	-350B	-385B
Foreign Exchange Rate Adjustments	-1.04B	-6.6B	17.98B	9.27B	246M
Miscellaneous Cash Flow Adjustments	-	-	-	-	-
Net Change in Cash	136B	138B	504B	-637B	13.43B
Supplemental Items
Cash Interest Paid	17.38B	14.87B	16.02B	22.67B	41.77B
Cash Income Tax Paid (Refund)	66.11B	64.44B	136B	217B	154B
Levered Free Cash Flow	123B	-394B	517B	-140B	-1,449B
Unlevered Free Cash Flow	129B	-389B	522B	-135B	-1,443B
Change In Net Working Capital	-15.11B	480B	-119B	465B	1,757B
Net Debt Issued / Repaid	-28.97B	277B	-35.59B	45.62B	622B

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	6.48	10.12	8.85	6.99	3.16
Return on Total Capital	7.36	11.87	10.52	8.2	3.38
Return On Equity %